Consumer beware: A systematic assessment of potential bias in the lay electronic media to examine the portrayal of "PARP" inhibitors for cancer treatment

Shawnta Coleman, Prema P. Peethambaram, Aminah Jatoi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This study examined how the lay electronic media covers poly-ADP-ribose polymerase, or "PARP," inhibitors, a class of cancer agents currently under clinical investigation. Of 771 internet links, 51 targeted the lay public. Independent review by two investigators yielded the following categorizations: 36 (71%) were "overly positive", 15 (29%) "neutral", and none "overly negative". "Overly positive" articles used: (l) overstated benefit, (2) included quotations from enthusiastic scientists, and (3) discussed single or small patient subsets. They used such phrases as "the holy grail of cancer research", "the most exciting development in cancer research in a decade or more⋯. it could save thousands of lives", and "we were surprised and delighted⋯. it's the kind of thing you don't really think will happen". Healthcare providers should be aware of the foregoing when discussing PARP inhibitors-and perhaps other novel therapies-with cancer patients.

Original languageEnglish (US)
Pages (from-to)474-477
Number of pages4
JournalJournal of Cancer Education
Volume26
Issue number3
DOIs
StatePublished - Sep 2011

Fingerprint

Neoplasms
Poly(ADP-ribose) Polymerases
Therapeutics
Research
Health Personnel
Internet
Research Personnel
Poly(ADP-ribose) Polymerase Inhibitors

Keywords

  • Cancer
  • Electronic media
  • Novel agents

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Oncology
  • Medicine(all)

Cite this

Consumer beware : A systematic assessment of potential bias in the lay electronic media to examine the portrayal of "PARP" inhibitors for cancer treatment. / Coleman, Shawnta; Peethambaram, Prema P.; Jatoi, Aminah.

In: Journal of Cancer Education, Vol. 26, No. 3, 09.2011, p. 474-477.

Research output: Contribution to journalArticle

@article{ff1cad0bfe1e419e9a8b406f4f1ee38c,
title = "Consumer beware: A systematic assessment of potential bias in the lay electronic media to examine the portrayal of {"}PARP{"} inhibitors for cancer treatment",
abstract = "This study examined how the lay electronic media covers poly-ADP-ribose polymerase, or {"}PARP,{"} inhibitors, a class of cancer agents currently under clinical investigation. Of 771 internet links, 51 targeted the lay public. Independent review by two investigators yielded the following categorizations: 36 (71{\%}) were {"}overly positive{"}, 15 (29{\%}) {"}neutral{"}, and none {"}overly negative{"}. {"}Overly positive{"} articles used: (l) overstated benefit, (2) included quotations from enthusiastic scientists, and (3) discussed single or small patient subsets. They used such phrases as {"}the holy grail of cancer research{"}, {"}the most exciting development in cancer research in a decade or more⋯. it could save thousands of lives{"}, and {"}we were surprised and delighted⋯. it's the kind of thing you don't really think will happen{"}. Healthcare providers should be aware of the foregoing when discussing PARP inhibitors-and perhaps other novel therapies-with cancer patients.",
keywords = "Cancer, Electronic media, Novel agents",
author = "Shawnta Coleman and Peethambaram, {Prema P.} and Aminah Jatoi",
year = "2011",
month = "9",
doi = "10.1007/s13187-010-0166-y",
language = "English (US)",
volume = "26",
pages = "474--477",
journal = "Journal of Cancer Education",
issn = "0885-8195",
publisher = "Springer Publishing Company",
number = "3",

}

TY - JOUR

T1 - Consumer beware

T2 - A systematic assessment of potential bias in the lay electronic media to examine the portrayal of "PARP" inhibitors for cancer treatment

AU - Coleman, Shawnta

AU - Peethambaram, Prema P.

AU - Jatoi, Aminah

PY - 2011/9

Y1 - 2011/9

N2 - This study examined how the lay electronic media covers poly-ADP-ribose polymerase, or "PARP," inhibitors, a class of cancer agents currently under clinical investigation. Of 771 internet links, 51 targeted the lay public. Independent review by two investigators yielded the following categorizations: 36 (71%) were "overly positive", 15 (29%) "neutral", and none "overly negative". "Overly positive" articles used: (l) overstated benefit, (2) included quotations from enthusiastic scientists, and (3) discussed single or small patient subsets. They used such phrases as "the holy grail of cancer research", "the most exciting development in cancer research in a decade or more⋯. it could save thousands of lives", and "we were surprised and delighted⋯. it's the kind of thing you don't really think will happen". Healthcare providers should be aware of the foregoing when discussing PARP inhibitors-and perhaps other novel therapies-with cancer patients.

AB - This study examined how the lay electronic media covers poly-ADP-ribose polymerase, or "PARP," inhibitors, a class of cancer agents currently under clinical investigation. Of 771 internet links, 51 targeted the lay public. Independent review by two investigators yielded the following categorizations: 36 (71%) were "overly positive", 15 (29%) "neutral", and none "overly negative". "Overly positive" articles used: (l) overstated benefit, (2) included quotations from enthusiastic scientists, and (3) discussed single or small patient subsets. They used such phrases as "the holy grail of cancer research", "the most exciting development in cancer research in a decade or more⋯. it could save thousands of lives", and "we were surprised and delighted⋯. it's the kind of thing you don't really think will happen". Healthcare providers should be aware of the foregoing when discussing PARP inhibitors-and perhaps other novel therapies-with cancer patients.

KW - Cancer

KW - Electronic media

KW - Novel agents

UR - http://www.scopus.com/inward/record.url?scp=80855129165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80855129165&partnerID=8YFLogxK

U2 - 10.1007/s13187-010-0166-y

DO - 10.1007/s13187-010-0166-y

M3 - Article

C2 - 20857352

AN - SCOPUS:80855129165

VL - 26

SP - 474

EP - 477

JO - Journal of Cancer Education

JF - Journal of Cancer Education

SN - 0885-8195

IS - 3

ER -